KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
Healthcare
$27.00 +0.00%
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
52W Low $9.83High $27.00
Volume 4.26M
Average 3.47M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$81.62M
FY 2026 · Annual
Investing Cash Flow
$18.68M
FY 2026 · Annual
-79.5% YoYFinancing Cash Flow
$162.64M
FY 2026 · Annual
+1.8% YoYCash Flow Statement
USD
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Depreciation & Amortization | 743K | 718K | 816K | 941K | 1.45M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 9.92M | 21.92M | 12.29M | 0 |
| Change in Working Capital | (12.32M) | 7.41M | 15.17M | 15.04M | 954K |
| Accounts Receivables | (5.2M) | (2.32M) | 8.18M | (3.62M) | (7.4M) |
| Inventory | 0 | 0 | 0 | 0 | (3.43M) |
| Accounts Payables | 1.69M | 1.11M | 4.32M | (4.97M) | 4.19M |
| Other Working Capital | (8.81M) | 8.62M | 2.67M | 23.63M | 7.59M |
| Other Non-Cash Items | 15.78M | (407K) | (485K) | 2.27M | 80.26M |
| Operating Cash Flow | (78.13M) | (75.26M) | (89.23M) | (152.91M) | (81.62M) |
| Capital Expenditures | (931K) | (1.2M) | (443K) | (434K) | (1.71M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (136.92M) | (98.25M) | (189.23M) | (30.57M) | (84.78M) |
| Sales of Investments | 195.71M | 140.86M | 104.96M | 122.52M | 105.36M |
| Other Investing Activities | 0 | 0 | (401K) | 0 | 0 |
| Investing Cash Flow | 57.86M | 41.42M | (84.72M) | 91.02M | 18.68M |
| Debt Repayment | 0 | 0 | 0 | 98.04M | 160.72M |
| Common Stock Issued | 1.58M | 56.58M | 96.95M | 61.69M | 1.92M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.53M | 53.77M | 0 | 0 |
| Financing Cash Flow | 1.58M | 58.12M | 150.71M | 159.73M | 162.64M |
| Effect of Forex Changes | (1.17M) | 1.24M | (1.21M) | 1.98M | (1.98M) |
| Net Change in Cash | (19.86M) | 25.51M | (24.45M) | 99.83M | 97.73M |
| Free Cash Flow | (79.07M) | (76.46M) | (89.67M) | (153.34M) | (83.33M) |
Free Cash Flow
Net Income to FCF bridge
FY2026
= Net Income-$164.3M
+ D&A$1.5M
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$954.0K
+ Other Non-Cash$80.3M
= Operating Cash Flow-$81.6M
- Capex-$1.7M
= Free Cash Flow-$83.3M
Analysis
FY2026 free cash flow is -$83.3M. FCF conversion is 50.7% of net income. Operating cash flow was -$81.6M, with capex of -$1.7M. The largest bridge item is Other Non-Cash at $80.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 |
Does KALV generate free cash flow?
KalVista Pharmaceuticals, Inc. (KALV) generated -$83.33M of free cash flow in fiscal 2026.
How much operating cash flow does KALV produce?
Operating cash flow was -$81.62M, before capital expenditures of $1.71M.
Continue the stock analysis
Jump to another research area for this company.